Timber Pharmaceuticals, Inc. (NYSE:TMBR) shares rose after gaining 21% on Tuesday. Timber Pharmaceuticals recently appointed Alan Mendelsohn as Chief Medical Officer.
"We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn recently supported the approval and launch of a new treatment for moderate to severe plaque psoriasis and has a deep understanding of clinical development and medical commercialization in dermatology," said John Koconis, Chief Executive Officer of Timber.
"We also thank Dr. Tavakkol for his support in establishing a strong scientific platform for us to build on as we advance into clinical stage research."
Mendelsohn is a board-certified pediatric cardiologist with more than 20 years of experience in clinical development and medical affairs. Prior to joining Timber, he served as Associate Vice president of Dermatology Medical Affairs for Sun Pharmaceuticals Industries.
Previously Mendelsohn led the U.S. rheumatology medical affairs team for Pfizer as a Senior Director and was Senior Director of Immunology Research and Development for Janssen where he worked on both rheumatology and dermatology indications.
He has also served in various leadership roles at Centocor, Inc., a Johnson & Johnson company. Mendelsohn holds a medical degree from the State University of New York Health Science Center at Brooklyn.
TMBR shares advanced four cents, or 2.7%, to $1.51.
